α-Synuclein and Parkinson's disease

FASEB Journal

Volumn 18, Issue 6, 2004, Pages 617-626

  Recchia, Alessandra ^a   Debetto, Patrizia ^a   Negro, Alessandro ^a   Guidolin, Diego ^a   Skaper, Stephen D ^b   Giusti, Pietro ^a,c  

^a UNIVERSITY OF PADOVA   (Italy)

^b GLAXOSMITHKLINE   (United Kingdom)

^c Dept of Pharmacol and Anesth ^*  (Italy)

Author keywords

synuclein aggregation; Animal models of Parkinson's disease; Dopaminergic neurons

Indexed keywords

ALPHA SYNUCLEIN; CELL PROTEIN; CHAPERONE; DOPAMINE; PROTEIN 14 3 3; SYNPHILIN 1; UNCLASSIFIED DRUG;

CELL LEVEL; CELL LOSS; CYTOPATHOGENIC EFFECT; DOPAMINERGIC NERVE CELL; ENVIRONMENTAL FACTOR; HEREDITY; HUMAN; MEMBRANE STABILIZATION; MOLECULAR MODEL; NERVE CELL PLASTICITY; NERVE ENDING; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN EXPRESSION; PROTEIN FOLDING; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; REVIEW;

ALPHA-SYNUCLEIN; AMINO ACID SEQUENCE; ANIMALS; DISEASE MODELS, ANIMAL; HUMANS; MOLECULAR SEQUENCE DATA; NERVE TISSUE PROTEINS; PARKINSON DISEASE; SYNUCLEINS;

ANIMALIA;

EID: 1842611727     PISSN: 08926638     EISSN: None     Source Type: Journal    
DOI: 10.1096/fj.03-0338rev     Document Type: Review

References (113)

1. Tanner, C. M. (1992) Occupational and environmental causes of parkinsonism. Occup. Med. 7, 503-513
2. Dluzen, D. E., and McDermott, J. L. (2000) Gender differences in neurotoxicity of the nigrostriatal dopaminergic system: implications for Parkinson's disease. J. Gend. Specif. Med. 3, 36-42
3. Lotharius, J., and Brundin, P. (2002) Pathogenesis of Parkinson's disease: dopamine, vesicles and alpha-synuclein. Nat. Rev. Neurosci. 3, 932-942
4. Siderowf, A., and Stern, M. (2003) Update on Parkinson disease. Ann. Intern. Med. 138, 651-658
5. Berrios, G. E., Campbell, C., and Politynska, B. E. (1995) Autonomic failure, depression and anxiety in Parkinson's disease. Br. J. Psychiatry 166, 789-792
6. Gomez-Tortosa, E., Newell, K., Irizarry, M. C., Albert, M., Growdon, J. H., and Hyman, B. T. (1999) Clinical and quantitative pathologic correlates of dementia with Lewy bodies. Neurology 53, 1284-1291
7. Warner, T. T., and Schapira, A.H. (2003) Genetic and environmental factors in the cause of Parkinson's disease. Ann. Neurol. 53 (Suppl. 3), S16-S23; discussion S23-S25
8. Polymeropoulos, M. H., Lavedan, C., Leroy, E., Ide, S. E., Dehejia, A., Dutra, A., Pike, B., Root, H., Rubenstein, J., Boyer, R., et al. (1997) Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 276, 2045-2047
9. Shimura, H., Schlossmacher, M. G., Hattori, N., Frosch, M. P., Trockenbacher, A., Schneider, R., Mizuno, Y., Kosik, K. S., and Selkoe, D. J. (2001) Ubiquitination of a new form of alpha-synuclein by parkin from human brain: implications for Parkinson's disease. Science 293, 263-269
10. Leroy, E., Boyer, R., Auburger, G., Leube, B., Ulm, G., Mezey, E., Harta, G., Brownstein, M. J., Jonnalagada, S., Chernova, T., et al. (1998) The ubiquitin pathway in Parkinson's disease. Nature (London) 395, 451-452
11. Bonifati, V., Rizzu, P., van Baren, M. J., Schaap, O., Breedveld, G.J., Krieger, E., Dekker, M. C., Squitieri, F., Ibanez, P., Joosse, M., et al. (2003) Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism. Science 299, 256-259
12. Polymeropoulos, M. H. (2000) Genetics of Parkinson's disease. Ann. N.Y. Acad. Sci. 920, 28-32
13. Nussbaum, R. L., and Ellis, C. E. (2003) Alzheimer's disease and Parkinson's disease. N. Engl. J. Med. 348, 1356-1364; erratum in. N. Engl. J. Med. 348, 2588
14. Nussbaum, R. L., and Ellis, C. E. (2003) Alzheimer's disease and Parkinson's disease. N. Engl. J. Med. 348, 1356-1364; erratum in. N. Engl. J. Med. 348, 2588
15. Dawson, T. M., and Dawson, V. L. (2003) Rare genetic mutations shed light on the pathogenesis of Parkinson disease. J. Clin. Invest. 111, 145-151
16. Spillantini, M. G., Schmidt, M. L., Lee, V. M., Trojanowski, J. Q., Jakes, R., and Goedert, M. (1997) Alpha-synuclein in Lewy bodies. Nature (London) 388, 839-840
17. Spillantini, M. G., Crowther, R. A., Jakes, R., Hasegawa, M., and Goedert, M. (1998) Alpha-synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with Lewy bodies. Proc. Natl. Acad. Sci. USA 95, 6469-6473
18. Uéda, K., Fukushima, H., Masliah, E., Xia, Y., Iwai, A., Yoshimoto, M., Otero, D. A., Kondo, J., Ihara, Y., and Saitoh, T. (1993) Molecular cloning of cDNA encoding an unrecognized component of amyloid in Alzheimer disease. Proc. Natl. Acad. Sci. USA 90, 11282-11286
19. George, J. M. (2002) The synucleins. Genome Biol. 3, 3002-3006
20. Iwai, A., Yoshimoto, M., Masliah, E., and Saitoh, T. (1995) The precursor protein of non-A beta component of Alzheimer's disease amyloid is a presynaptic protein of the central nervous system. Neuron 14, 467-475
21. Nakajo, S., Shioda, S., Nakai, Y., and Nakaya, K. (1994) Localization of phosphoneuroprotein 14 (PNP 14) and its mRNA expression in rat brain determined by immunocytochemistry and in situ hybridisation. Brain Res. Mol. Brain Res. 27, 81-86
22. Lavedan, C. (1998) The synuclein family. Genome Res. 8, 871-880
23. Spillantini, M. G., Divane, A., and Goedert, M. (1995) Assignment of human alpha-synuclein (SNCA) and beta-synuclein (SNCB) genes to chromosomes 4q21 and 5q35. Genomics 27, 379-381
24. Maroteaux, L., Campanelli, J. T., and Scheller, R. H. (1988) Synuclein: a neuron-specific protein localized to the nucleus and presynaptic nerve terminal. J. Neurosci. 8, 2804-2815
25. Eliezer, D., Kutluay, E., Bussell, R., Jr., and Browne, G. (2001) Conformational properties of alpha-synuclein in its free and lipid-associated states. J. Mol. Biol. 307, 1061-1073
26. Li, J., Uversky, V. N., and Fink, A. L. (2001) Effect of familial PD point mutations A30P and A53T on the structural properties, aggregation and fibrillation of human α-syn. Biochemistry 40, 11604-11613
27. Kahle, P. J., Haass, C., Kretzschmar, H. A., and Neumann, M. (2002) Structure/function of alpha-synuclein in health and disease: rational development of animal models for Parkinson's and related diseases. J. Neurochem. 82, 449-457
28. Chandra, S., Chen, X., Rizo, J., Jahn, R., and Sudho, T. C. (2003) A broken α-helix in folded α-synuclein. J. Biol. Chem. 278, 15313-15318
29. Uversky, V. N., and Fink, A. L. (2002) Amino acid determinants of alpha-synuclein aggregation: putting together pieces of the puzzle. FEBS Lett. 522, 9-13
30. Davidson, W. S., Jonas, A., Clayton, D. F., and George, J. M. (1998) Stabilization of alpha-synuclein secondary structure upon binding to synthetic membranes. J. Biol. Chem. 273, 9443-9449
31. Conway, K. A., Rochet, J. C., Bieganski, R. M., and Lansbury, P. T., Jr. (2001) Kinetic stabilization of the alpha-synuclein protofibril by a dopamine-alpha-synuclein adduct. Science 294, 6-9
32. Lee, H. J., Choi, C., and Lee, S. J. (2002) Membrane-bound alpha-synuclein has a high aggregation propensity and the ability to seed the aggregation of the cytosolic form. J. Biol. Chem. 277, 671-678
33. Lee, H.J., Shin, S. Y., Choi, C., Lee, Y. H., and Lee, S.J. (2002) Formation and removal of alpha-synuclein aggregates in cells exposed to mitochondrial inhibitors. J. Biol. Chem. 277, 5411-5417
34. Clayton, D. F., and George, J. M. (1999) Synucleins in synaptic plasticity and neurodegenerative disorders. J. Neurosci. Res. 58, 120-129
35. Kruger, R., Kuhn, W., Muller, T., Woitalla, D., Graeber, M., Kosel, S., Przuntek, H., Epplen, J. T., Schols, L., and Riess, O. (1998) Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease. Nat. Genet. 18, 106-108
36. Rochet, J. C., Conway, K. A., and Lansbury, P. T. (2000) Inhibition of fibrillization and accumulation of prefibrillar oligomers in mixtures of human and mouse α-synuclein. Biochemistry 39, 10619-10626
37. Giasson, B. I., Murray, I. V. J., Trojanowski, J. Q., and Lee, V. M. (2001) A hydrophobic stretch of 12 amino acid residues in the middle of α-synuclein is essential for filament assembly. J. Biol. Chem. 276, 2380-2386
38. El-Agnaf, O. M., and Irvine, G. B. (2002) Aggregation and neurotoxicity of alpha-synuclein and related peptides. Biochem. Soc. Trans. 30, 559-565
39. Okochi, M., Walter, J., Koyama, A., Nakajo, S., Baba, M., Iwatsubo, T., Meijer, L., Kahle, P. J., and Haass, C. (2000) Constitutive phosphorylation of the Parkinson's disease associated alpha-synuclein. J. Biol. Chem. 275, 390-397
40. Souza, J. M., Giasson, B. I., Chen, Q., Lee, V. M., and Ischiropoulos, H. (2000) Dityrosine cross-linking promotes formation of stable alpha-synuclein polymers. Implication of nitrative and oxidative stress in the pathogenesis of neurodegenerative synucleinopathies. J. Biol. Chem. 275, 18344-18349
41. Kim, T. D., Paik, S. R., and Yang, C. H. (2002) Structural and functional implications of C-terminal regions of alpha-synuclein. Biochemistry 41, 13782-13790
42. Park, S. M., Jung, H. Y., Kim, T. D., Park, J. H., Yang, C. H., and Kim, J. (2002) Distinct roles of the N-terminal-binding domain and the C-terminal-solubilizing domain of α-synuclein, a molecular chaperone. J. Biol. Chem. 277, 28512-28520
43. Negro, A., Brunati, A. M., Donella-Deana, A., Massimino, M. L., and Pinna, L. A. (2002) Multiple phosphorylation of alpha-synuclein by protein tyrosine kinase Syk prevents eosin-induced aggregation. FASEB J. 16, 210-212
44. Ellis, C. E., Schwartzberg, P. L., Grider, T. L., Fink, D. W., and Nussbaum, R. L. (2001) Alpha-synuclein is phosphorylated by members of the Src family of protein-tyrosine kinases. J. Biol. Chem. 276, 3879-3884
45. Nakamura, T., Yamashita, H., Takahashi, T., and Nakamura, S. (2001) Activated Fyn phosphorylates alpha-synuclein at tyrosine residue 125. Biochem. Biophys. Res. Commun. 280, 1085-1092
46. Pronin, A. N., Morris, A. J., Surguchov, A., and Benovic, J. L. (2000) Synucleins are a novel class of substrates for G protein-coupled receptor kinases. J. Biol. Chem. 275, 26515-26522
47. Fujiwara, H., Hasegawa, M., Dohmae, N., Kawashima, A., Masliah, E., Goldberg, M. S., Shen, J., Takio, K., and Iwatsubo, T. (2002) Alpha-synuclein is phosphorylated in synucleinopathy lesions. Nat. Cell Biol. 4, 160-164
48. McLean, P.J., and Hyman, B. T. (2002) An alternatively spliced form of rodent alpha-synuclein forms intracellular inclusions in vitro: role of the carboxy-terminus in alpha-synuclein aggregation. Neurosci. Lett. 323, 219-223
49. Takahashi, T., Yamashita, H., Nakamura, T., Nagano, Y., and Nakamura, S. (2002) Tyrosine 125 of alpha-synuclein plays a critical role for dimerization following nitrative stress. Brain Res. 938, 73-80
50. Crowther, R. A., Jakes, R., Spillantini, M. G., and Goedert, M. (1998) Synthetic filaments assembled from C-terminally truncated α-synuclein. FEBS Lett. 436, 309-312
51. George, J. M., Jin, H., Woods, W. S., and Clayton, D. F. (1995) Characterization of a novel protein regulated during the critical period for song learning in the zebra finch. Neuron 15, 361-372
52. Jenco, J. M., Rawlingson, A., Daniels, B., and Morris, A. J. (1998) Regulation of Phospholipase D2: selective inhibition of mammalian phospholipase D isoenzymes by alpha- and beta-synucleins. Biochemistry 37, 4901-4909
53. Chen, Y. G., Siddhanta, A., Austin, C. D., Hammond, S. M., Sung, T. C., Frohman, M. A., Morris, A. J., and Shields, D. (1997) Phospholipase D stimulates release of nascent secretory vesicles from the trans-Golgi network. J. Cell Biol. 138, 495-504
54. Rajagopalan, S., and Andersen, J. K. (2001) Alpha-synuclein aggregation: is it the toxic gain of function responsible for neurodegeneration in Parkinson's disease? Mech. Ageing Dev. 122, 1499-1510
55. Abeliovich, A., Schmitz, Y., Farinas, I., Choi-Lundberg, D., Ho, W. H., Castillo, P. E., Shinsky, N., Verdugo, J. M., Armanini, M., Ryan, A., et al. (2000) Mice lacking alpha-synuclein display functional deficits in the nigrostriatal dopamine system. Neuron 25, 239-252
56. Murphy, D. D., Rueter, S. M., Trojanowski, J. Q., and Lee, V. M. (2000) Synucleins are developmentally expressed, and alpha-synuclein regulates the size of the presynaptic vesicular pool in primary hippocampal neurons. J. Neurosci. 20, 3214-3220
57. Slavotinek, A. M., and Biesecker, L. G. (2003) Unfolding the role of chaperones and chaperonins in human disease. Trends Genet. 17, 528-535
58. Ostrerova, N., Petrucelli, L., Farrer, M., Mehta, N., Choi, P., Hardy, J., and Wolozin, B. (1999) Alpha-synuclein shares physical and functional homology with 14-3-3 proteins. J. Neurosci. 19, 5782-5791
59. Xu, J., Kao, S. Y., Lee, F.J., Song, W., Jin, L. W., and Yankner, B. A. (2002) Dopamine-dependent neurotoxicity of alpha-synuclein: a mechanism for selective neurodegeneration in Parkinson disease. Nat. Med. 8, 600-606
60. Boston, P. F., Jackson, P., and Thompson, R. J. (1982) Human 14-3-3 protein, radioimmunoassay, tissue distribution, and cerebrospinal fluid levels in patients with neurological disorders. J. Neurochem. 38, 1475-1482
61. Fu, H., Subramanian, R. R., and Masters, S. C. (2000) 14-3-3 proteins: structure, function and regulation. Annu. Rev. Pharmacol. Toxicol. 40, 617-647
62. Yuan, J., and Yanker, B. A. (2000) Apoptosis in the nervous system. Nature (London) 407, 802-809
63. Conway, K. A., Harper, J. D., and Lansbury, P. T. (1998) Accelerated in vitro fibril formation by a mutant alpha-synuclein linked to early-onset Parkinson disease. Nat. Med. 11, 1318-1320
64. McKeith, I. G., Burn, D. J., Ballard, C. G., Collerton, D., Jaros, E., Morris, C. M., McLaren, A., Perry, E. K., Perry, R., Piggott, M. A., et al. (2003) Dementia with Lewy bodies. Semin. Clin. Neuropsychiatry 8, 46-57
65. Suh, Y. H., and Checler, F. (2002) Amyloid precursor protein, presenilins, and alpha-synuclein: molecular pathogenesis and pharmacological applications in Alzheimer's disease. Pharmacol. Rev. 54, 469-525
66. Simard, M., and van Reekum, R. (2001) Dementia with Lewy bodies in Down's syndrome. Int. J. Geriatr. Psychiatry 16, 311-320
67. Burn, D. J., and Jaros, E. (2001) Multiple system atrophy: cellular and molecular pathology. Mol. Pathol. 54, 419-426
68. Arai, K., Kato, N., Kashiwado, K., and Hattori, T. (2000) Pure autonomic failure in association with human alpha-synucleinopathy. Neurosci. Lett. 296, 171-173
69. Mochizuki, A., Komatsuzaki, Y., and Shoji, S. (2002) Association of Lewy bodies and glial cytoplasmic inclusions in the brain of Parkinson's disease. Acta Neuropathol. (Berlin) 104, 534-537
70. Dickson, D. W., Liu, W., Hardy, J., Farrer, M., Mehta, N., Uitti, R., Mark, M., Zimmerman, T., Golbe, L., Sage, J., et al. (1999) Widespread alterations of alpha-synuclein in multiple system atrophy. Am. J. Pathol. 155, 1241-1251
71. Saito, Y., Kawai, M., Inoue, K., Sasaki, R., Arai, H., Nanba, E., Kuzuhara, S., Ihara, Y., Kanazawa, I., and Murayama, S. (2000) Widespread expression of alpha-synuclein and tau immunoreactivity in Hallervorden-Spatz syndrome with protracted clinical course. J. Neurol. Sci. 177, 48-59
72. Newell, K. L., Boyer, P., Gomez-Tortosa, E., Hobbs, W., Hedley-Whyte, E. T., Vonsattel, J. P., and Hyman, B. T. (1999) Alpha-synuclein immunoreactivity is present in axonal swellings in neuroaxonal dystrophy and acute traumatic brain injury. J. Neuropathol. Exp. Neurol. 58, 1263-1268
73. Forman, M. S., Schmidt, M. L., Kasturi, S., Perl, D. P., Lee, V. M., and Trojanowski, J. Q. (2002) Tau and alpha-synuclein pathology in amygdala of Parkinsonism-dementia complex patients of Guam. Am. J. Pathol. 160, 1725-1731
74. Spillantini, M. G., Tolnay, M., Love, S., and Goedert, M. (1999) Microtubule-associated protein tau, heparan sulphate and alpha-synuclein in several neurodegenerative diseases with dementia. Acta Neuropathol. (Berlin) 97, 585-594
75. Biere, A. L., Wood, S. J., Wypych, J., Steavenson, S., Jiang, Y., Anafi, D., Jacobsen, F. W., Jarosinski, M. A., Wu, G. M., Louis, J. C., et al. (2000) Parkinson's disease-associated alpha-synuclein is more fibrillogenic than beta- and gamma-synuclein and cannot cross-seed its homologs. J. Biol. Chem. 275, 34574-34579
76. Serpell, L. C., Berriman, J., Jakes, R., Goedert, M., and Crowther, R. A. (2000) Fiber diffraction of synthetic alpha-synuclein filaments shows amyloid-like cross-beta conformation. Proc. Natl. Acad. Sci. USA 97, 4897-4902
77. Kahle, P.J., Neumann, M., Ozmen, L., Muller, V., Jacobsen, H., Schindzielorz, A., Okochi, M., Leimer, U., van Der Putten, H., Probst, A., et al. (2000) Subcellular localization of wild-type and Parkinson's disease-associated mutant alpha-synuclein in human and transgenic mouse brain. J. Neurosci. 20, 6365-6373
78. Forno, L. S. (1996) Neuropathology of Parkinson's disease. Neuropathol. Exp. Neurol. 55, 259-272
79. Galvin, J. E., Uryu, K., Lee, V. M., and Trojanowski, J. Q. (1999) Axon pathology in Parkinson's disease and Lewy body dementia hippocampus contains alpha-, beta-, and gamma-synuclein. Proc. Natl. Acad. Sci. USA 96, 13450-13455
80. Wood, S. J., Wypych, J., Steavenson, S., Louis, J. C., Citron, M., and Biere, A. L. (1999) α-Synuclein fibrillogenesis is nucleation-dependent. Implications for the pathogenesis of Parkinson's disease. J. Biol. Chem. 274, 19509-19512
81. Volles, M. J., and Lansbury, P. T., Jr. (2002) Vesicle permeabilization by protofibrillar alpha-synuclein is sensitive to Parkinson's disease-linked mutations and occurs by a pore-like mechanism. Biochemistry 41, 4595-4602
82. Conway, K. A., Lee, S.J., Rochet, J. C., Ding, T. T., Williamson, R. E., and Lansbury, P. T., Jr. (2000) Acceleration of oligomerization, not fibrillization, is a shared property of both alpha-synuclein mutations linked to early-onset Parkinson's disease: implications for pathogenesis and therapy. Proc. Natl. Acad. Sci. USA 97, 571-576
83. Conway, K. A., Harper, J. D., and Lansbury, P. T., Jr. (2000) Fibrils formed in vitro from alpha-synuclein and two mutant forms linked to Parkinson's disease are typical amyloid. Biochemistry 39, 2552-2563
84. Ciechanover, A. (2001) Linking ubiquitin, parkin and synphilin-1. Nat. Med. 7, 1108-1109
85. McNaught, K., Belizaire, R., Isacson, O., Jenner, P., and Olanow, C. W. (2003) Altered proteasomal function in sporadic Parkinson's disease. Exp. Neurol. 179, 38-46
86. Voges, D., Zwickl, P., and Baumeister, W. (1999) The 26S proteasome: a molecular machine designed for controlled proteolysis. Annu. Rev. Biochem. 68, 1015-1068
87. Gibb, W. R., and Lees, A. J. (1988) The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease. J. Neurol. Neurosurg. Psychiatry 51, 745-752
88. Iwatsubo, T., Yamaguchi, H., Fujimuro, M., Yokosawa, H., Ihara, Y., Trojanowski, J. Q., and Lee, V. M. (1996) Purification and characterization of Lewy bodies from the brains of patients with diffuse Lewy body disease. Am. J. Pathol. 148, 1517-1529
89. Chung, K. K., Zhang, Y., Lim, K. L., Tanaka, Y., Huang, H., Gao, J., Ross, C. A., Dawson V. L., and Dawson, T. M. (2001) Parkin ubiquitinates the alpha-synuclein-interacting protein, synphilin-1: implications for Lewy-body formation in Parkinson disease. Nat. Med. 7, 1144-1150
90. West, A., Periquet, M., Lincoln, S., Lucking, C. B., Nicholl, D., Bonifati, V., Rawal, N., Gasser, T., Lohmann, E., Deleuze, J. F., et al. (2002) Complex relationship between Parkin mutations and Parkinson disease. Am. J. Med. Genet. 114, 584-591
91. Hashimoto, M., Hsu, L. J., Xia, Y., Takeda, A., Sisk, A., Sundsmo, M., and Masliah, E. (1999) Oxidative stress induces amyloid-like aggregate formation of NACP/alpha-synuclein in vitro. NeuroReport 10, 717-721
92. Goldberg, M. S., and Lansbury, P. T., Jr. (2000) Is there a cause-and-effect relationship between alpha-synuclein fibrillization and Parkinson's disease? Nat. Cell Biol. 2, E115-E119
93. Ostrerova-Golts, N., Petrucelli, L., Hardy, J., Lee, J. M., Farer, M., and Wolozin, B. (2000) The A53T alpha-synuclein mutation increases iron-dependent aggregation and toxicity. J. Neurosci. 20, 6048-6054
94. Jenner, P., and Olanow, C. W. (1998) Understanding cell death in Parkinson's disease. Ann. Neurol. 44, Suppl. 1, S72-S84
95. Beckman, J. S., Beckman, T. W., Chen, J., Marshall, P. A., and Freeman, B. A. (1990) Apparent hydroxyl radical production by peroxynitrite: implications for endothelial injury from nitric oxide and superoxide. Proc. Natl. Acad. Sci. USA 87, 1620-1624
96. Jenner, P. (1998) Oxidative mechanisms in nigral cell death in Parkinson's disease. Mov. Disord. 13, 24-34
97. Zigmond, M. J., Hastings, T. G., and Perez, R. G. (2002) Increased dopamine turnover after partial loss of dopaminergic neurons: compensation or toxicity. Parkinsonism Relat. Disord. 8, 389-393
98. Jones, D. C., Gunasekar, P. G., Borowitz, J. L., and Isom, G. E. (2000) Dopamine-induced apoptosis is mediated by oxidative stress and is enhanced by cyanide in differentiated PC12 cells. J. Neurochem. 74, 2296-2304
99. Berg, D., Gerlach, M., Youdim, M. B., Double, K. L., Zecca, L., Riederer, P., and Becker, G. (2001) Brain iron pathways and their relevance to Parkinson's disease. J. Neurochem. 79, 225-236
100. Ilic, T., Jovanovic, M., Jovicic, A., and Tomovic, M. (1998) Oxidative stress and Parkinson's disease. Vojnosanit. Pregl. 55, 463-468
101. Riederer, P., Sofic, E., Rausch, W. D., Schmidt, B., Reynolds, G. P., Jellinger, K., and Youdim, M. B. (1989) Transition metals, ferritin, glutathione, and ascorbic acid in parkinsonian brains. J. Neurochem. 52, 515-520
102. Junn, E., and Mouradian, M. (2002) Human α-synuclein over-expression increases intracellular reactive oxygen species levels and susceptibility to dopamine. Neurosci. Lett. 320, 146-150
103. Rabinovic, A. D., Lewis, D. A., and Hastings, T. G. (2000) Role of oxidative changes in the degeneration of dopamine terminals after injection of neurotoxic levels of dopamine. Neuroscience 101, 67-76
104. Zigmond, R. E., Schwarzschild, M. A., and Rittenhouse, A. R. (1989) Acute regulation of tyrosine hydroxylase by nerve activity and by neurotransmitters via phosphorylation. Annu. Rev. Neurosci. 12, 415-461
105. Perez, R. G., Waymire, J. C., Lin, E., Liu, J. J., Guo, F., and Zigmond, M. J. (2002) A role for alpha-synuclein in the regulation of dopamine biosynthesis. J. Neurosci. 22, 3090-3099
106. Baptista, M.J., O'Farrell, C., Daya, S., Ahmad, R., Miller, D. W., Hardy, J., Farrer, M.J., and Cookson, M. R. (2003) J. Neurochem. 85, 957-968
107. Dawson, T. M., Mandir, A., and Lee, M. (2002) Animal models of PD: pieces of the same puzzle? Neuron 35, 219-222
108. Beal, M. F. (2001) Experimental models of Parkinson's disease. Nat. Rev. Neurosci. 2, 325-334
109. Betabert, R., Sherer, T. B., and Greenamyre, J. T. (2002) Animal models of Parkinson's diseases. Bioessays 24, 308-318
110. McNaught, K. S., Bjorklund, L. M., Belizaire, R., Isacson, O., Jenner, P., and Olanow, C. W. (2002) Proteasome inhibition causes nigral degeneration with inclusion bodies in rats. NeuroReport 13, 1437-1441
111. Lee, M. K., and Price, D. L. (2001) Advances in genetic models of Parkinson's disease. Clin. Neurosci. Res. 1, 456-466
112. Lo Bianco, C., Ridet, J. L., Schneider, B. L., Deglon, N., and Aebischer, P. (2002) Alpha-synucleinopathy and selective dopaminergic neuron loss in a rat lentiviral-based model of Parkinson's disease. Proc. Natl. Acad. Sci. USA 99, 10813-10818
113. Kirik, D., Rosenblad, C., Burger, C., Lundberg, C., Johansen, T. E., Muzyczka, N., Mandel, R. J., and Bjorklund, A. (2002) Parkinson-like neurodegeneration induced by targeted overexpression of alpha-synuclein in the nigrostriatal system. J. Neurosci. 22, 2780-2791